Erik de Vrieze, theme Sensory Disorders, aims to develop a new form of genetic therapy for patients with hereditary deafness. The therapy is designed for patients with a mutation in DFNA9, the most common mutation found in hereditary deafness in patients in the Netherlands and Belgium.The ZonMw Off Road subsidy is meant to give young researchers the opportunity to test their groundbreaking hypothesis and to develop this innovative idea into a proof of concept. Applications should be characterized by their high-risk profile and unconventional research methods ('high risk, high gain' projects). Specifically, the research should be fundamental (pilot data are not needed), in the field of (bio)medical of health sciences and concerns the development of technologies for a durable health system.
This year ZonMw granted Erik de Vrieze an Off Road subsidy:
Erik de Vrieze, theme Sensory Disorders, aims to develop a new form of genetic therapy for patients with hereditary deafness. The therapy is designed for patients with a mutation in DFNA9, the most common mutation found in hereditary deafness in patients in the Netherlands and Belgium.
We have two copies of most genes: one paternally inherited, the other comes from the mother. Patient with a mutation in DFNA9 have mutation in only one of these copies. De Vrieze: “One normally functional copy of DFNA9 in principle would be sufficient for the generation of functional protein to prevent deafness. However, in this case, the protein translated from the mutated gene sticks to the normal protein rendering the normal protein unable to exert its function. Therefore, patient with only one mutated copy of DFNA9 still develop deafness.
There is currently no therapy for these patients. Erik de Vrieze aims to develop a therapy by making use of CRISPR-Cas technology. With this technique he can specifically block the mutated DFNA9 protein so it no longer sticks to the healthy protein.
Erik de Vrieze
Related news items
Frank Walboomers 25-years work anniversary at Radboudumc17 September 2020
Frank Walboomers, associate professor at the research group Regenerative Biomaterials at the Dept. of Dentistry (theme Reconstructive & Regenerative Medicine), celebrated his 25th work anniversary at Radboudumc.read more
Tjitske Kleefstra appointed endowed professor of Clinical genetics and psychopathology of rare syndromes17 September 2020
Tjitske Kleefstra has been appointed endowed professor of Clinical genetics and psychopathology of rare syndromes at the department of Neurodevelopmental disorders, with effect from 1 September.read more
Annette Schenck appointed professor of Translational Genetics17 September 2020
Annette Schenck has been appointed professor of Translational Genetics at the department of Neurodevelopmental disorders, with effect from 1 August. The chair will bring together fundamental and translational research in the field of brain developmental disorders.read more
Transfer of new anti-hepatitis C drugs across the human placenta9 September 2020
In a recent publication in American Journal of Obstetrics and Gynecology, researchers from the Departments of Pharmacology and Toxicology, Pharmacy, Obstetrics and Gynecology, Gastroenterology and Hepatology, investigated the placental passage of two such drugs for the first time.read more
Nanda Rommelse appointed endowed professor of Neurodevelopmental disorders8 September 2020
Nanda Rommelse has been appointed professor of Neurodevelopmental disorders with effect from 1 September. The chair will function as a bridge between the Psychiatry Department of the Radboudumc with Karakter Child and Adolescent Psychiatry.read more
Does the COVID-19 cytokine storm exist? Research may have an impact on the chances of success of a specific treatment4 September 2020
Following the measurement of several important cytokines in patients with COVID-19 and various other severe diseases, researchers at Radboud university medical center now show that COVID-19 is not characterized by a cytokine storm.read more